Ranked by reported Q2 2026 13F market value
Share of total reported institutional value in PYXS held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | GordonMD Global Investments LP | 10.0M | $30.2M | +143.2% | 15.823% | 14.60% |
| 2 | PFIZER INC | 7.0M | $19.5M | 0.0% | 11.101% | 11.43% |
| 3 | Laurion Capital Management LP | 4.9M | $14.8M | -1.9% | 7.735% | 0.38% |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 2.1M | $6.2M | +2.1% | 3.277% | 0.00% |
| 5 | Atle Fund Management AB | 966K | $2.9M | +390.5% | 1.525% | 0.78% |
| 6 | BlackRock, Inc. | 868K | $2.6M | +10.0% | 1.370% | 0.00% |
| 7 | Palo Alto Investors LP | 864K | $2.6M | -14.5% | 1.364% | 0.12% |
| 8 | MARSHALL WACE, LLP | 831K | $2.5M | +134.3% | 1.311% | 0.00% |
| 9 | RENAISSANCE TECHNOLOGIES LLC | 772K | $2.3M | -13.1% | 1.219% | 0.00% |
| 10 | GEODE CAPITAL MANAGEMENT, LLC | 592K | $1.8M | -1.1% | 0.934% | 0.00% |
| 11 | Woodline Partners LP | 524K | $1.6M | — | 0.827% | 0.00% |
| 12 | 683 Capital Management, LLC | 459K | $1.4M | -48.8% | 0.725% | 0.07% |
| 13 | JACOBS LEVY EQUITY MANAGEMENT, INC | 429K | $1.3M | -7.0% | 0.676% | 0.00% |
| 14 | DIADEMA PARTNERS LP | 388K | $1.2M | — | 0.613% | 0.15% |
| 15 | JANE STREET GROUP, LLC | 364K | $1.1M | +10.3% | 0.574% | 0.00% |
| 16 | Longaeva Partners L.P. | 354K | $1.1M | -29.7% | 0.558% | 0.02% |
| 17 | Decheng Capital LLC | 327K | $984K | 0.0% | 0.516% | 0.13% |
| 18 | VANGUARD FIDUCIARY TRUST CO | 303K | $912K | +0.7% | 0.478% | 0.00% |
| 19 | STATE STREET CORP | 249K | $749K | 0.0% | 0.393% | 0.00% |
| 20 | MILLENNIUM MANAGEMENT LLC | 233K | $701K | -41.4% | 0.368% | 0.00% |
| 21 | UBS Group AG | 155K | $467K | -38.9% | 0.245% | 0.00% |
| 22 | Bank of New York Mellon Corp | 134K | $403K | 0.0% | 0.212% | 0.00% |
| 23 | NORTHERN TRUST CORP | 124K | $373K | +21.6% | 0.196% | 0.00% |
| 24 | NewEdge Wealth, LLC | 116K | $349K | 0.0% | 0.183% | 0.00% |
| 25 | XTX Topco Ltd | 111K | $334K | -44.6% | 0.175% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in PYXS — a direct measure of their conviction.
Filings activity in PYXS during Q2 2026, grouped by how each filer changed its position.
Institutions that opened a new PYXS position in Q2 2026
Institutions that fully closed their PYXS position in Q2 2026
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q2 2026 | 79 | +1.3% | 54.76% | +10.61 pp | $102M | +153% |
| Q1 2026 | 78 | +0.0% | 44.15% | 4.51 pp | $41M | +15% |
| Q4 2025 | 78 | +6.8% | 48.66% | +5.40 pp | $35M | 41% |
| Q3 2025 | 73 | 2.7% | 43.26% | 1.11 pp | $59M | +98% |
| Q2 2025 | 75 | 16% | 44.37% | 4.78 pp | $30M | +1.7% |
| Q1 2025 | 89 | 11% | 49.15% | 4.89 pp | $30M | 41% |
| Q4 2024 | 100 | +11% | 54.04% | +12.14 pp | $50M | 45% |
| Q3 2024 | 90 | — | 41.90% | — | $91M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Institutional ownership and quarterly buying activity across the largest Oncology Biotech peers.
Quick answers to the most common questions about buying PYXS stock.
Based on Q2 2026 13F filings, institutional ownership of Pyxis Oncology, Inc. stands at 54.8%, held across 79 reporting institutions.
GordonMD Global Investments LP is the largest reported institutional holder of PYXS, with approximately 10,024,909 shares worth $0.03B as of Q2 2026.
Yes — 3 widely-followed marquee investors appear among the top 25 institutional holders of PYXS, including RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, MILLENNIUM MANAGEMENT LLC.
Our composite Smart Money Score for PYXS is 73 out of 100 (Bullish). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
11 institutions opened new positions in PYXS during Q2 2026, while 8 fully exited. 65 added to existing positions and 3 trimmed.
PYXS institutional ownership rose by 10.61 percentage points quarter-over-quarter, with a net change of +1 holders.
The top 10 institutions account for 83.4% of all reported 13F value in PYXS, and the top 25 account for 95.9%.
Across the largest Oncology Biotech peers, institutional ownership levels are: DMRA (200.0%), FTH (54.5%), LONA (184.4%), KYNB (26.9%), CNSY (4.8%). See the peer comparison table on this page for net buyer activity by company.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.